1,3-苯并噻唑-2-羧酸乙酯 | 32137-76-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 1,3-苯并噻唑-2-羧酸乙酯
• 中文别名: 2-苯并噻唑羧酸乙酯；苯并噻唑-2-甲酸乙酯；苯并噻唑-2-羧酸乙酯；苯并噻吩-2-甲酸乙酯
• 英文名称: benzothiazole-2-carboxylic acid ethyl ester
• 英文别名: ethyl benzothiazole-2-carboxylate；ethyl benzo[d]thiazole-2-carboxylate；ethyl 1,3-benzothiazole-2-carboxylate；2-ethoxycarbonylbenzothiazole；ethyl 2-benzothiazolecarboxylate；ethyl benzo[d]thiazole‐2‐carboxylate；Benzothiazol-2-carbonsaeure-aethylester；2-carboxyethylbenzothiazol
• CAS: 32137-76-1
• 化学式: C₁₀H₉NO₂S
• mdl: MFCD00848360
• 分子量: 207.253
• InChiKey: VLQLCEXNNGQELL-UHFFFAOYSA-N

物化性质

• 熔点：
  68-72 °C
• 沸点：
  312.8±25.0 °C(Predicted)
• 密度：
  1.290±0.06 g/cm3(Predicted)
• 最大波长(λmax)：
  287nm(CHCl3)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934999090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Ethyl benzothiazole-2-carboxylate
CAS-No. : 32137-76-1

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 2-Benzothiazolecarboxylic acid ethyl ester
Formula : C10H9NO2S
Molecular Weight : 207,25 g/mol
Component Concentration
Ethyl benzothiazole-2-carboxylate
CAS-No. 32137-76-1 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Sulphur oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Avoid
breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 68 - 72 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion
May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-苯并噻唑-2-羧酸乙酯 在 sodium tetrahydroborate 、 三苯基膦 作用下， 以 甲醇 、 四氯化碳 、 苯 为溶剂， 反应 4.0h， 生成 2-氯甲基-1,3-苯并噻唑
  参考文献：
  名称：

  噻唑基亚甲基三苯基磷杂环戊烷及其苯并衍生物：合成乙烯基噻唑和乙烯基苯并的稳定和实用的wittig试剂：醛的二碳同系化

  摘要：

  标题的噻唑基磷烷是一种稳定但反应性很强的维蒂希型试剂，与各种醛反应后，可以很好的收率得到主要或仅作为异构体的乙烯基噻唑。而且，与文献报道不同，苯并噻唑基磷烷衍生物证明与醛反应。从噻唑核上进行甲酰基解封的乙烯基噻唑提供了两个碳均化的饱和醛。例如，这些乙烯基噻唑之一，即。β-苯基衍生物8f，证明在甲酰基解封3-苯基庚醛后加-丁基丁基锂锂得到。

  DOI：

  10.1016/s0040-4020(01)90345-x
• 作为产物：
  描述：

  2-ethoxycarbonylmethyl-2-ethoxycarbonyl-2,3-dihydro-1,3-benzothiazole 以65%的产率得到1,3-苯并噻唑-2-羧酸乙酯
  参考文献：
  名称：

  Liso, Gaetano; Trapani, Giuseppe; Latrofa, Andrea, Journal of Heterocyclic Chemistry, 1987, vol. 24, p. 1683 - 1684

  摘要：

  DOI：

文献信息

• Synthesis and characterization of novel benzothiazole amide derivatives and screening as possible antimitotic and antimicrobial agents
  作者：Mahesh Bhat、S. L. Belagali、N. K. Hemanth Kumar、S. Mahadeva Kumar

  DOI：10.1007/s11164-016-2627-3

  日期：2017.1

  that of standard drug (14.4 %), while the remaining compounds showed lower mitotic index values; hence, these compounds inhibit the regular cell division process and are the most promising antimitotic agents. Based on the structural activity relationship, the maximum percentage inhibition was observed for compounds containing electron-withdrawing group, revealing enhanced antimitotic activity, while compounds

  摘要合成了 一系列新的苯并噻唑酰胺衍生物（ 9a - l ），并通过傅里叶变换红外光谱（FT-IR），质谱，1 H和13 C核磁共振（NMR）光谱进行了表征。通过 葱属 测定法确定新合成的化合物的抗有丝分裂活性 ，由此计算出有丝分裂指数值。分别是 9克 （14.0％）和9 升 （14.5％）的有丝分裂指数值与标准药物（14.4％）最相近，而其余化合物的有丝分裂指数值较低；因此，这些化合物抑制正常的细胞分裂过程，是最有希望的抗有丝分裂剂。基于结构活性关系，含有吸电子基团的化合物观察到最大抑制百分数，显示出增强的抗有丝分裂活性，而带有电子给体的化合物如呋喃（ 9g ）和甲基（ 9l ）与标准品相当。还对新合成的化合物进行了抗菌活性筛选，其中一些具有显着活性。 图形概要
• Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
  申请人：——

  公开号：US20030073707A1

  公开（公告）日：2003-04-17

  The invention provides compounds of Formula I: 1 wherein W 0 is a bicyclic moiety and is 2 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which &agr;7 is known to be involved.

  这项发明提供了Formula I的化合物： 其中W0是一个双环基团，是 这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物，对治疗已知涉及α7的疾病或症状有用。
• Hydrogenation of Esters to Alcohols with a Well-Defined Iron Complex
  作者：Svenja Werkmeister、Kathrin Junge、Bianca Wendt、Elisabetta Alberico、Haijun Jiao、Wolfgang Baumann、Henrik Junge、Fabrice Gallou、Matthias Beller

  DOI：10.1002/anie.201402542

  日期：2014.8.11

  We present the first base‐free Fe‐catalyzed ester reduction applying molecular hydrogen. Without any additives, a variety of carboxylic acid esters and lactones were hydrogenated with high efficiency. Computations reveal an outer‐sphere mechanism involving simultaneous hydrogen transfer from the iron center and the ligand. This assumption is supported by NMR experiments.

  我们展示了第一个使用分子氢的无碱铁催化的酯还原反应。在没有任何添加剂的情况下，各种羧酸酯和内酯被高效地氢化。计算揭示了一种外球机理，涉及同时从铁中心和配体转移氢。NMR实验支持这一假设。
• Novel hybrids of benzothiazole-1,3,4-oxadiazole-4-thiazolidinone: Synthesis, in silico ADME study, molecular docking and in vivo anti-diabetic assessment
  作者：Rubina Bhutani、Dharam Pal Pathak、Garima Kapoor、Asif Husain、Md. Azhar Iqbal

  DOI：10.1016/j.bioorg.2018.10.025

  日期：2019.3

  olidinone hybrid analogs (Tz1-Tz28) were synthesized in search of potential anti-diabetic agents. Molecular docking study was conducted with binding pocket of peroxisome proliferator activated receptor-gamma to elucidate the binding interactions of newly synthesized targets. Seven selected compounds with best docking scores were further screened for in vivo anti-hyperglycemic efficacy by oral glucose

  为了寻找潜在的抗糖尿病药，合成了一系列新的苯并噻唑-1,3,4-恶二唑-4-噻唑烷酮杂合体（Tz1-Tz28）。用过氧化物酶体增殖物激活的受体-γ的结合袋进行分子对接研究，以阐明新合成靶标的结合相互作用。通过口服糖耐量试验，在非糖尿病大鼠和链脲佐菌素诱导的糖尿病大鼠模型中，进一步筛选了七个对接得分最高的化合物，以进行体内抗高血糖药效研究。所有测试的化合物均显示出极佳的中度降低血糖水平。三种化合物（Tz21，Tz7和Tz10）通过将葡萄糖浓度降低至157.15±1.79 mg / dL，154.39±1.71 mg / dL，167.36±2.45 mg / dL表现出优异的抗糖尿病作用，分别优于标准药物吡格列酮178.32±1.88 mg / dL。此外，IC50值分别为0.21±0.01 µM，9.03±0.12 µM和11.96±0.40 µM的三种衍生物Tz21，Tz4和Tz24也显
• Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties
  作者：Aya E. Ghonim、Alessia Ligresti、Alessandro Rabbito、Ali Mokhtar Mahmoud、Vincenzo Di Marzo、Noha A. Osman、Ashraf H. Abadi

  DOI：10.1016/j.ejmech.2019.07.002

  日期：2019.10

  strong therapeutic potential of CB2 receptor agonists for use as anti-inflammatory agents that lack psychiatric side effects has attracted substantial interest. We herein describe the rational design and synthesis of novel thiazole and benzothiazole derivatives and the evaluation of their binding affinity and functional activity on CB1 and CB2 receptors. The series with the general formula N-(3-pentylbenzo

  CB 2受体激动剂用作缺乏精神病副作用的抗炎药的强大治疗潜力引起了人们的极大兴趣。我们在本文中描述了新型噻唑和苯并噻唑衍生物的合理设计和合成，以及它们对CB1和CB2受体的结合亲和力和功能活性的评估。具有通式的串联ñ - （3-戊基苯并[ d ]噻唑-2（3 H ^） -亚基）甲酰胺（化合物6A-6D）显示出朝向CB 2受体具有最高的亲和力和选择性与ķ我S IN皮摩尔或低纳摩尔范围和选择性指数（K i hCB1 / K ihCB2）达到429倍。值得注意的是，在低纳摩尔范围内的EC 50 s的细胞测定中，这些化合物还显示出激动性功能活性。更有趣的是，化合物6d（3-（三氟甲基）苯甲酰胺衍生物）在小鼠模型中表现出显着的抗DSS诱导的急性结肠炎的保护作用。

表征谱图